Indefinite Delivery Contract 75D30124D18657
Award Date
4/1/24
Last Date to Order
3/31/25
Federal Agency
CDC Pittsburgh
Awardee
Pfizer Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. to purchase a variety of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.5 billion contract has a period of performance from April 1, 2023 to March 31, 2024. The contract will procure a minimum of 100 doses up to maximum quantities ranging from 100,000 to 13 million doses for 21...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $1,517,947,500.00 and a period of performance from April 1, 2022 through March 31, 2023. It is a multiple award contract vehicle that will provide up to 23 standard pediatric vaccines to support CDC's Immunization Awardees and the Vaccines for...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc., a large pharmaceutical manufacturer, to support the Vaccines for Children (VFC) program. The $2,208,581,100 contract, which spans April 1, 2025 through March 30, 2026, will provide a range of standard commercial pediatric vaccines to eligible children, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or have...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc. to supply a variety of standard pediatric vaccines over a 12-month period. The contract, valued at up to $1,530,970,000, will support the CDC's Vaccines for Children program, which provides immunizations to eligible children. The contract covers 20 different pediatric vaccines, including DTaP, Hepatitis A and B, Hib, HPV, MMR, Pneumococcal, Rotavirus, and Varicella, with minimum...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc. for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children aged 0 through 18 years. The contract has a $1,075,250,000.00 ceiling value and a performance period ending on June 6, 2024. The vaccines procured under this multiple-award IDC will support pediatric immunization programs through the Vaccines...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), to Sanofi Pasteur Inc., a major global vaccine manufacturer, to procure a wide range of pediatric vaccines. The $1.793 billion multiple-award IDC covers the period from April 1, 2024 to March 31, 2025, with the vaccines intended to support the CDC's Immunization Awardees program and Vaccines for Children (VFC) program. The...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, for the procurement of pediatric COVID-19 vaccines. The contract has a total ceiling value of $1,009,243,769 and a period of performance from June 1, 2025, through May 31, 2026. The primary objective of this IDC is to provide the CDC with a reliable source for pediatric COVID-19 vaccines to support the Vaccines for Children (VFC)...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. for the purchase of various adult vaccines. The $118.2 million contract, running from July 1, 2024 to June 30, 2025, covers a diverse array of vaccines including Hepatitis, HPV, Measles/Mumps/Rubella, Meningococcal, Mpox, Pneumococcal, and Varicella. The contract does not utilize any set-asides and allows for...